Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC) Meeting Abstract
| Authors: | El Dika, I. H.; Geyer, S. M.; Nixon, A. B.; Innocenti, F.; Shi, Q.; Jacobson, S. B.; Yaqubie, A.; Lopez, J. C.; Huang, B. H.; Tang, Y. W.; Wen, Y. J.; Schwartz, L. H.; Bertagnolli, M. M.; Meyerhardt, J. A.; O'Reilly, E. M.; Venook, A. P.; Abou-Alfa, G. K. |
| Abstract Title: | Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC) |
| Meeting Title: | 2021 Gastrointestinal Cancers Symposium (ASCO GI) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2021 Jan 15-17 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-01-20 |
| Language: | English |
| ACCESSION: | WOS:000636712800342 |
| DOI: | 10.1200/JCO.2021.39.3_suppl.325 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 325 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work